Highlights

• Sun Pharma has received a series of buy ratings from leading brokerage and research firms.

• Sun Pharma secured a major regulatory milestone with the FDA approving a label update for UNLOXCYT™, supported by long-term clinical data showing improved outcomes in advanced cutaneous squamous cell carcinoma.

• The company expands its market presence through a new partnership with AstraZeneca to expand nationwide access to Sodium Zirconium Cyclosilicate for patients living with hyperkalaemia.

Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA) has attracted a wave of optimism from major research and brokerage firms, all of whom have issued buy ratings accompanied by upward-leaning target prices.

HSBC Global Investment Research has assigned a buy rating with a target price of INR 1,915, while Nirmal Bang Institutional Equities has also reiterated a buy stance, projecting the stock to reach INR 2,054. Further bolstering market sentiment, Centrum Broking Private Limited has issued its own buy recommendation with a target price of INR 1,990. HDFC Securities Institutional Research, too, has aligned with this positive view, setting a target of INR 2,000 alongside a buy rating.

With all four institutions converging on a similar bullish outlook, Sun Pharma stands out as one of the favored pharmaceutical stocks in the current market landscape.

Regulatory Milestone: FDA Approves Label Update for UNLOXCYT™

On 26 November 2025, Sun Pharma announced a significant regulatory development with the U.S. FDA’s approval of a label update for UNLOXCYT™ (cosibelimab-ipdl). The update is grounded in longer-term clinical data demonstrating enhanced outcomes for patients with advanced cutaneous squamous cell carcinoma (aCSCC).

UNLOXCYT remains the first and only PD-L1 immune checkpoint inhibitor approved for aCSCC, marking a notable step forward in immuno-oncology. Its continued demonstration of durable responses positions it as a valued treatment option for patients who often present with additional comorbidities.

Long-term follow-up from the pivotal open-label study showed improved objective response rates, with more than 50% of patients achieving a measurable response. The median duration of response was not reached in either study cohort at the time of analysis, highlighting the sustained benefit observed. Importantly, the safety profile of UNLOXCYT remained unchanged.

The updated clinical findings have also been published in the Journal of the American Academy of Dermatology, reinforcing the scientific validity of the results.

Strategic Partnership to Expand Access to Hyperkalaemia Treatment

In another key announcement on 17 November 2025, Sun Pharma revealed a strategic collaboration with AstraZeneca Pharma India Limited to enhance access to Sodium Zirconium Cyclosilicate (SZC) for patients across India. This marks the second brand partnership between the companies for the same therapy.

Under the agreement, AstraZeneca will market the product under the brand name Lokelma®, while Sun Pharma will promote it as Gimliand®. Both companies will jointly expand availability, with AstraZeneca retaining intellectual property rights and the marketing authorisation.

Disclaimer:

The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

Copyright 2025 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.